Exclusive special offer and discount title banner vector image

ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Asia-Pacific Skin Cancer Diagnostics Market by Type (Melanoma, Non-melanoma) Market by Gender (Male, Female) Market by Screening Type (Skin Biopsy, Dermatoscopy, Lymph Node, Biopsy Imaging Tests, Blood Tests) by Geography


MARKET OVERVIEW

The Asia-Pacific skin cancer diagnostics market is anticipated to generate $1524.40 million by 2032, propelling at a 7.76% CAGR during the forecast years between 2023-2032.

The Asia-Pacific region is witnessing the expansion of healthcare infrastructure and increased R&D expenditure, which is anticipated to generate new prospects for the skin cancer diagnostics market. Efforts in skin cancer awareness campaigns and educational initiatives have intensified, fostering greater awareness about early detection and regular screenings. Consequently, the demand for diagnostic tests has risen, driven by the growing emphasis on early detection and screenings. This surge in demand for screening tools and techniques is propelling the market growth.

To Know More About This Report, Request a Free Sample Copy

The Asia-Pacific skin cancer diagnostics market growth analysis includes a thorough study of Australia & New Zealand, Vietnam, China, Indonesia, South Korea, Japan, Thailand, India, and Rest of Asia-Pacific. In China, melanoma has been a concerning rise in skin cancer over the past few decades. In 2017, the age-standardized incidence rate of melanoma was 9 per 100,000, reflecting a significant increase of 110.3% since 1990. The burden of melanoma on public health has also become apparent, as indicated by the disability-adjusted life-years (DALYs), which experienced a significant increase of 13.6% annually from 2007 to 2017, resulting in an age-standardized rate of 7.6 per 100,000 in 2017.

The economic impact of melanoma on patients in Hunan, China, is substantial, with median spending reaching nearly 60% of the average annual disposable income. Specifically, middle-aged men with melanoma on their limbs face the highest financial burden associated with the disease. Additionally, skin cancer has emerged as a pressing public health concern in China. Recent data from the World Health Organization (WHO) revealed that skin cancer deaths accounted for 19,669 or 0.20% of total deaths in China. Recognizing the issue’s significance, China has incorporated cancer prevention and control as a major special action in its ‘Healthy China Action (2019-2030)’ initiative.

Moreover, the demand for cancer care in China is evident, as cancer hospitals received over 22 million patient visits in 2020, albeit slightly lower than the previous year. Between 2010 and 2019, treatment visits steadily increased, with figures in 2019 tripling compared to 2010. As the incidence of skin cancer continues to rise, and new technologies and diagnostic tools become available, the skin cancer diagnostic market in China is projected to grow, providing healthcare providers and patients with improved capabilities in diagnosis and treatment. 

The Asia-Pacific skin cancer diagnostics market segmentation evaluation entails gender, type, and screening type. Market by type covers melanoma and non-melanoma.

Melanoma, a highly dangerous form of skin cancer, is characterized by its aggressive growth and ability to spread to any organ. Originating from melanocytes, the cells responsible for producing skin pigment, melanoma typically appears as black or brown but manifests in pink, red, purple, or skin-colored variations.

Although melanoma represents only 1% of all skin cancers, it accounts for most skin cancer-related deaths. It is particularly prevalent among individuals under 30, predominantly affecting young women. The incidence of melanoma has seen a significant increase over the past three decades, largely attributed to heightened exposure to ultraviolet (UV) radiation, a major contributing factor to the rise in cases.

Leading companies operating in the Asia-Pacific skin cancer diagnostics market include Michelson Diagnostics Ltd, AMLo Biosciences Limited, etc.

AMLo Biosciences Ltd is a company that operates in the Biotechnology industry. The company provides a prognostic test for detecting early AJCC Stage I and Stage II melanoma. The company’s product includes AMBLor, a diagnostic test based on two protein markers, AMBRA1 and loricrin (AMLo), in the upper epidermis layer. It is headquartered in Newcastle upon Tyne, United Kingdom.

AMBLor® from AMLo Biosciences Ltd is a development test based on two protein markers normally present in the upper layer of the skin (epidermis).

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Gender, Type, and Screening Type
Countries AnalyzedChina, Japan, India, South Korea, Indonesia, Vietnam, Thailand, Australia & New Zealand, and Rest of Asia-Pacific
Companies AnalyzedAMLo Biosciences Limited, bioMérieux SA, Castle Biosciences Inc, DermLite LLC, DermTech Inc, F Hoffmann-La Roche Ltd, Michelson Diagnostics Ltd, NeraCare GmbH, SkylineDx BV, Veriskin Inc

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
      1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS
      2. EXPANDING MARKET DEMAND FOR SKIN CANCER DIAGNOSTICS IN AUSTRALIA
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. INCREASING PREVALENCE OF SKIN CANCER
      2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
      3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
    2. KEY RESTRAINTS
      1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
      2. STRINGENT REGULATORY FRAMEWORK
      3. LACK OF SKILLED MEDICAL PROFESSIONALS
  4. KEY ANALYTICS
    1. PARENT MARKET ANALYSIS
    2. KEY MARKET TRENDS
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
    5. MARKET CONCENTRATION ANALYSIS
    6. VALUE CHAIN ANALYSIS
      1. RESEARCH AND DEVELOPMENT
      2. MANUFACTURING
      3. MARKETING AND SALES
      4. DISTRIBUTION AND LOGISTICS
      5. TRAINING AND SUPPORT
  5. MARKET BY TYPE
    1. MELANOMA
    2. NON-MELANOMA
  6. MARKET BY GENDER
    1. MALE
    2. FEMALE
  7. MARKET BY SCREENING TYPE
    1. SKIN BIOPSY
    2. DERMATOSCOPY
    3. LYMPH NODE
    4. BIOPSY IMAGING TESTS
    5. BLOOD TESTS
  8. GEOGRAPHICAL ANALYSIS
    1. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET DRIVERS
      3. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. PRODUCT LAUNCHES & DEVELOPMENTS
      2. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. AMLO BIOSCIENCES LIMITED
      2. BIOMERIEUX SA
      3. CASTLE BIOSCIENCES INC
      4. DERMLITE LLC
      5. DERMTECH INC.
      6. F HOFFMANN-LA ROCHE LTD
      7. MICHELSON DIAGNOSTICS LTD
      8. NERACARE GMBH
      9. SKYLINEDX BV
      10. VERISKIN INC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – SKIN CANCER DIAGNOSTICS

TABLE 2: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: KEY PLAYERS OPERATING IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET

TABLE 11: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 12: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC

FIGURE 4: MARKET CONCENTRATION ANALYSIS

FIGURE 5: VALUE CHAIN ANALYSIS

FIGURE 6: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 7: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY MELANOMA, 2023-2032 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY NON-MELANOMA, 2023-2032 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY GENDER, IN 2022

FIGURE 10: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY MALE, 2023-2032 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY FEMALE, 2023-2032 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY SCREENING TYPE, IN 2022

FIGURE 13: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY SKIN BIOPSY, 2023-2032 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY DERMATOSCOPY, 2023-2032 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY LYMPH NODE, 2023-2032 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY BIOPSY IMAGING TESTS, 2023-2032 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY BLOOD TESTS, 2023-2032 (IN $ MILLION)

FIGURE 18: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 19: CHINA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 20: JAPAN SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 21: INDIA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 22: SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 23: INDONESIA SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 24: THAILAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 25: VIETNAM SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 26: AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 27: REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, 2023-2032 (IN $ MILLION)

FAQ’s